文献速递糖尿病甲状腺疾病

胰高血糖素样肽1受体激动剂与甲状腺癌风险:一项国际多中心队列研究

Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study.
PubMed 文献 · Thyroid · 2025-01-08

该多中心队列研究纳入加拿大、丹麦、挪威、韩国、瑞典和台湾六个数据库的2型糖尿病患者,比较胰高血糖素样肽1受体激动剂(GLP1-RA)与二肽基肽酶4抑制剂(DPP-4i)使用者的甲状腺癌风险。汇总加权HR为0.81(CI 0.59-1.12),未发现GLP1-RA使用与甲状腺癌风险增加相关,但随访时间短(中位1.8至3.0年),不足以排除长期使用的超额风险。

要点

  • GLP1-RA使用与DPP-4i相比,甲状腺癌风险汇总加权HR为0.81(CI 0.59-1.12),无显著增加。
  • 在GLP1-RA曾使用者中,随累积剂量增加未见甲状腺癌风险升高。
  • 随访时间短(中位1.8至3.0年),证据不足以排除长期使用时的超额风险。

核心结论

  • 在六个基于人群的数据库的大型多中心研究中,未发现GLP1-RA使用与甲状腺癌风险增加相关的证据,随访时间为1.8至3.0年。
  • 由于随访时间短,证据不足以排除长期使用时的超额风险。

研究设计与样本

  • 国际多中心队列研究,后续进行荟萃分析,纳入加拿大(安大略)、丹麦、挪威、韩国、瑞典和台湾六个基于人群的数据库。
  • 研究人群为2007年至2023年间的2型糖尿病患者,共识别98,147名GLP1-RA使用者和2,488,303名DPP-4i使用者。

主要发现

  • GLP1-RA使用者与DPP-4i使用者相比,甲状腺癌的汇总加权HR为0.81(CI 0.59-1.12)。
  • 在GLP1-RA曾使用者中,随累积剂量增加未见甲状腺癌风险升高。
  • 甲状腺癌类型的亚组分析无法进行。
  • 结果在一系列补充分析中保持一致。

局限性

  • 随访时间短,中位随访在GLP1-RA使用者中为1.8至3.0年,证据不足以排除长期使用时的超额风险。
  • 甲状腺癌类型的亚组分析无法进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Introduction: Concerns have been raised that glucagon-like peptide 1 receptor agonists (GLP1-RAs) may increase the risk of thyroid cancer, but evidence remains conflicting. We therefore investigated if GLP1-RA use, compared with use of dipeptidyl peptidase-4 inhibitors (DPP-4is), was associated with thyroid cancer risk in patients with type 2 diabetes. Methods: This multisite cohort study with subsequent meta-analysis included six population-based databases from Canada (Ontario), Denmark, Norway, South Korea, Sweden, and Taiwan. Study populations comprised patients with type 2 diabetes between 2007 and 2023. Cox regression models estimated hazard ratios (HR) and 95% confidence intervals (CIs) for thyroid cancer among GLP1-RA users compared with DPP-4is. Models were weighted using standardized mortality ratio weights generated from time-specific propensity scores. Site-specific HRs were pooled using a fixed-effects model. Results: We identified 98,147 users of GLP1-RA and 2,488,303 users of DPP-4i, with the median follow-up among users of GLP1-RA ranging from 1.8 to 3.0 years. Overall, use of GLP1-RA relative to use of DPP-4i was not associated with an increased risk of thyroid cancer (pooled weighted HR 0.81, CI 0.59-1.12). Similarly, we observed no increased risk in thyroid cancer with increasing cumulative dose of GLP1-RA among GLP1-RA ever-users. Subgroup analysis of types of thyroid cancer was not possible. Results remained consistent across a range of supplementary analyses. Discussion: In this large multisite study, utilizing data from six population-based databases, we found no evidence that GLP1-RA use is associated with an increased risk of thyroid cancer with follow-up ranging from 1.8 to 3.0 years, providing some reassurance to patients and clinicians about the short-term safety of these drugs. Nevertheless, evidence was insufficient to rule out excess risk with long-term use, due to the short follow-up.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Baxter SM, Lund LC, Andersen JH, et al. Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study. Thyroid. 2025. PMID: 39772758. doi:10.1089/thy.2024.0387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。